Chemistry and Biology of Mitragynine Alkaloids

帽柱木碱生物碱的化学和生物学

基本信息

  • 批准号:
    10203899
  • 负责人:
  • 金额:
    $ 60.12万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2018
  • 资助国家:
    美国
  • 起止时间:
    2018-09-01 至 2023-06-30
  • 项目状态:
    已结题

项目摘要

SUMMARY Chemistry and Biology of Mitragynine Alkaloids ! Mitragynine is a corynanthe-type indole alkaloid representing the major psychoactive constituent of Mitragyna speciosa (also known as “kratom”), a plant native to Southeast Asia. The use of kratom has been on the rise in the U.S. in the last decade, to such an extent that it attracted the attention of the Drug Enforcement Administration (DEA). Despite the initial intent by the DEA to place two alkaloids of this plant, mitragynine and 7-hydroxymitragynine (7OH), into Schedule I of the Control Substance Act, the DEA eventually withdrew this action following dramatic opposition from the public. Thus, kratom remains a readily available “opioid material” in the U.S. and most other countries worldwide. At the same time, the basic science underlying the biological effects of kratom remains poorly understood. The proposed research addresses an urgent need for a systematic examination of mitragynine alkaloids and builds on extensive preliminary results generated by the PIs. We have recently reported that mitragynine is a partial mu-opioid receptor (MOR) agonist with a G protein-biased signaling profile. In addition, we have found that mitragynine is metabolized to 7OH, a more potent, G protein-biased MOR agonist. Furthermore, we have shown that 7OH induces potent analgesia in mice without respiratory depression and constipation side effects, and thus, represents an attractive atypical opioid template for further investigations. In this application, we focus on mapping the basic science of mitragynine and its metabolite 7OH in terms of synthetic methods, metabolism, receptor signaling and pharmacological profile,!by pursuing three integrated aims. Moreover, we aim to explore the central hypothesis that G protein-biased MOR agonism underlies the favorable separation of analgesia and side effects exhibited by mitragynine-type compounds. These goals will be accomplished by an interdisciplinary team with significant experience in synthetic and computational chemistry, opioid receptor signaling, and in vitro and in vivo pharmacology.
摘要 三叶草碱类生物碱的化学和生物学研究 好了! 米特拉吉宁是一种洋参碱型吲哚生物碱,代表了木犀草素的主要精神活性成分 原产于东南亚的一种植物--光叶菊属。KrATOM的使用一直是 关于美国在过去十年中的崛起,以至于引起了毒品的注意 执行管理局(DEA)。尽管DEA最初打算放置这种植物的两种生物碱, 将三氢呋喃和7-羟基三氢呋喃(7OH)纳入《控制物质法》附表一,即DEA 在遭到公众的强烈反对后,最终撤回了这一行动。因此,KrATOM仍然是一个现成的 在美国和世界上大多数其他国家都有“阿片类物质”。同时,基本的 KrATOM生物效应背后的科学仍然知之甚少。拟议的研究 解决了对三叶生物碱进行系统检查的迫切需要,并建立在广泛的 PIS生成的初步结果。我们最近报道了米拉吉宁是一种部分阿片类药物。 受体(MOR)激动剂,具有G蛋白偏向的信号转导。此外,我们还发现,米曲吉宁是 代谢到7OH,一种更有效的偏重于G蛋白的MOR激动剂。此外,我们已经证明了7OH 对小鼠有很强的镇痛作用,没有呼吸抑制和便秘副作用,因此, 代表了一个有吸引力的非典型阿片类药物模板,用于进一步研究。在本应用程序中,我们重点介绍 绘制合成方法方面的米曲尼宁及其代谢物7OH的基础科学图, 代谢、受体信号和药理特性,!追求三个综合目标。此外, 我们的目标是探索中心假设,即G蛋白偏向的MOR激动症是有利的 三氢呋喃类化合物的止痛和副作用的分离。这些目标将是 由在合成和计算领域拥有丰富经验的跨学科团队完成 化学、阿片受体信号、体外和体内药理学。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(1)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Susruta Majumdar其他文献

Susruta Majumdar的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Susruta Majumdar', 18)}}的其他基金

Pharmacological Probes based on mitragynine pseudoindoxyl
基于帽柱木碱假吲哚酚的药理探针
  • 批准号:
    9765241
  • 财政年份:
    2018
  • 资助金额:
    $ 60.12万
  • 项目类别:
Pharmacological Probes based on mitragynine pseudoindoxyl
基于帽柱木碱假吲哚酚的药理探针
  • 批准号:
    10209056
  • 财政年份:
    2018
  • 资助金额:
    $ 60.12万
  • 项目类别:
Chemistry and Biology of Mitragynine Alkaloids
帽柱木碱生物碱的化学和生物学
  • 批准号:
    9765285
  • 财政年份:
    2018
  • 资助金额:
    $ 60.12万
  • 项目类别:
Chemistry and Biology of Mitragynine Alkaloids
帽柱木碱生物碱的化学和生物学
  • 批准号:
    10436844
  • 财政年份:
    2018
  • 资助金额:
    $ 60.12万
  • 项目类别:
Analgesics targeting truncated 6transmembrane exon 11 variants of MOR-1 (6TM-E11)
针对 MOR-1 (6TM-E11) 截短的 6 跨膜外显子 11 变体的镇痛药
  • 批准号:
    8869092
  • 财政年份:
    2012
  • 资助金额:
    $ 60.12万
  • 项目类别:
Analgesics targeting truncated 6transmembrane exon 11 variants of MOR-1 (6TM-E11)
针对 MOR-1 (6TM-E11) 截短的 6 跨膜外显子 11 变体的镇痛药
  • 批准号:
    8542812
  • 财政年份:
    2012
  • 资助金额:
    $ 60.12万
  • 项目类别:
Analgesics targeting truncated 6transmembrane exon 11 variants of MOR-1 (6TM-E11)
针对 MOR-1 (6TM-E11) 截短的 6 跨膜外显子 11 变体的镇痛药
  • 批准号:
    8353038
  • 财政年份:
    2012
  • 资助金额:
    $ 60.12万
  • 项目类别:

相似海外基金

Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
  • 批准号:
    MR/S03398X/2
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
  • 批准号:
    EP/Y001486/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
  • 批准号:
    2338423
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
  • 批准号:
    MR/X03657X/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
  • 批准号:
    2348066
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
  • 批准号:
    2341402
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
  • 批准号:
    AH/Z505481/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10107647
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
  • 批准号:
    10106221
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
  • 批准号:
    AH/Z505341/1
  • 财政年份:
    2024
  • 资助金额:
    $ 60.12万
  • 项目类别:
    Research Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了